evolocumab - medicine shortage information

Back to ALL shortages and discontinuations Back to CRITICAL shortages and discontinuations

If you are having difficulty obtaining a medicine that has been prescribed to you, talk to your doctor or pharmacist to discuss suitable options to continue your care.

More information about medicine shortages and how to access alternative medicines is available at the Medicine Shortages hub

Sort by: Updated date | Shortage status | Trade name

Product details	Supply Impact Dates	Further Details
REPATHA evolocumab (rch) 420 mg/3.5 mL injection solution automated mini-doser AMD AUST R: 348651 Active ingredients: evolocumab Dosage form: Injection, solution Sponsor: Amgen Australia Pty Ltd Phone: 1800 803 638	Deletion from market: 14 Jul 2024	Shortage status: Discontinued Availability: Reduction in supply until supply is exhausted Reason: Manufacturing Management action: This product will be replaced by an alternative presentation - REPATHA evolocumab (rch) 140 mg/mL injection solution syringe within a pen injector ARTG 231152. The sponsor is reserving some stock of REPATHA AMD (ARTG 348651) to ensure continuity of supply to specific patient groups during the transition to the alternative presentation. For more information, please contact Amgen Medical Information Australia on 1800 803 638.

Product details

Supply Impact Dates

Further Details

REPATHA evolocumab (rch) 420 mg/3.5 mL injection solution automated mini-doser AMD
AUST R: 348651
Active ingredients:
evolocumab

Dosage form:
Injection, solution

Sponsor:
Amgen Australia Pty Ltd

Phone:
1800 803 638

Deletion from market:
14 Jul 2024

Shortage status:
Discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Manufacturing

Management action:
This product will be replaced by an alternative presentation - REPATHA evolocumab (rch) 140 mg/mL injection solution syringe within a pen injector ARTG 231152.
The sponsor is reserving some stock of REPATHA AMD (ARTG 348651) to ensure continuity of supply to specific patient groups during the transition to the alternative presentation. For more information, please contact Amgen Medical Information Australia on 1800 803 638.